Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS)

CNY 8.28

(-0.12%)

Market Cap (In CNY)

16.14 Billion

Revenue (In CNY)

3.07 Billion

Net Income (In CNY)

1.16 Billion

Avg. Volume

13.42 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.02-11.09
PE
-
EPS
-
Beta Value
0.272
ISIN
CNE000000H87
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Sheng Leng Chun
Employee Count
-
Website
https://www.thdb.com
Ipo Date
1994-08-24
Details
Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. Its lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, and insulin lispro; antidiabetic drugs; and oral hypoglycemic drugs, as well as Gan Shulin pens, blood glucose meters, and other medical devices. It offers building materials. The company has a strategic alliance with Adocia. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is based in Tonghua, China.